Сингапур - английский - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - varicella virus vaccine live (oka/merck) - injection - 2700 pfu/ml - varicella virus vaccine live (oka/merck) 2700 pfu/ml

Сингапур - английский - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - rabies immune globulin (human) - injection - 150 iu/ml - rabies immune globulin (human) 300 iu/ml

Сингапур - английский - HSA (Health Sciences Authority)

pfizer private limited - alprostadil - injection - 0.5 mg/ml - alprostadil 0.5 mg/ml

Австралия - английский - Department of Health (Therapeutic Goods Administration)

becton dickinson pty ltd - 47903 - infusion pump medication dosage application software - a various group of softwre programs, routines or algorithms that enable the user to create, maintain, modify and store delivery parameters (protocols) for delivery of medication by an infusion pump which is used in a hospital or institution or used for ambulatory purposes. a set of applications programs and routines may be included with such infusion/syringe pumps and they can be upgraded to add new system capabilities. applications program packages are typically identified by a proprietary name and "version" or "upgrade" number- an example being (not limited too) alaris system manager and guardrails editor software.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - 47903 - infusion pump medication dosage application software - a standalone drug library editor application that allows the user the ability to create, configure and store facility-specific drug library file parameters and alerts for future transfer into a dedicated infusion or syringe pump through a compatible communication interface software.

ЮАР - английский - South African Health Products Regulatory Authority (SAHPRA)

ranbaxy (sa) (pty) ltd - injection - see ingredients - each vial contains esomeprazole 40,0 mg

Армения - английский - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ever pharma jena gmbh - apomorphine hydrochloride hemihydrate - solution for injection - 10mg/ml

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - omalizumab, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 20; histidine; arginine hydrochloride; histidine hydrochloride monohydrate; water for injections - allergic asthma,children 6 to < 12 years of age - in children aged 6 to <12 years, xolair is indicated as add-on therapy to improve asthma control in patients with severe allergic asthma who have documented exacerbations despite daily high dose inhaled corticosteroids, and who have immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,adults and adolescents 12 years of age and above -xolair is indicated for the management of adult and adolescent patients with moderate to severe allergic asthma, who are already being treated with inhaled steroids, and who have serum immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,chronic rhinosinusitis with nasal polyps (crswnp),xolair is indicated as add-on treatment in adult patients (18 years of age and above) for the treatment of severe crswnp with inadequate response to intranasal corticosteroids. recommended dosing is determined by serum immunoglobulin e levels and body weight corresponding to the recommended dose range in the product information (see section 4.2 dose and method of administration).,chronic spontaneous urticaria (csu),xolair is indicated for adults and adolescents (12 years of age and above) with chronic spontaneous urticaria who remain symptomatic despite h1 antihistamine treatment.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - omalizumab, quantity: 75 mg - injection, solution - excipient ingredients: arginine hydrochloride; water for injections; histidine; histidine hydrochloride monohydrate; polysorbate 20 - allergic asthma,children 6 to < 12 years of age - in children aged 6 to <12 years, xolair is indicated as add-on therapy to improve asthma control in patients with severe allergic asthma who have documented exacerbations despite daily high dose inhaled corticosteroids, and who have immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,adults and adolescents 12 years of age and above -xolair is indicated for the management of adult and adolescent patients with moderate to severe allergic asthma, who are already being treated with inhaled steroids, and who have serum immunoglobulin e levels corresponding to the recommended dose range (see table 1 in section 4.2 dose and method of administration).,chronic rhinosinusitis with nasal polyps (crswnp),xolair is indicated as add-on treatment in adult patients (18 years of age and above) for the treatment of severe crswnp with inadequate response to intranasal corticosteroids. recommended dosing is determined by serum immunoglobulin e levels and body weight corresponding to the recommended dose range in the product information (see section 4.2 dose and method of administration).,chronic spontaneous urticaria (csu),xolair is indicated for adults and adolescents (12 years of age and above) with chronic spontaneous urticaria who remain symptomatic despite h1 antihistamine treatment.

Канада - английский - Health Canada

pharmascience inc - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents